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Abstract
Genetic determinants that are associated with preeclampsia still remain elusive
nowadays, which might have resulted from limited understanding of the underlying
pathogenesis mechanisms and the fetal contributions. By using genome-wide association
study approach, we identified 2 candidate copy number deletions of the highest odds ratio
ranking on chromosome 1 and 19, from 283 US white babies born by the mothers with
preeclampsia. Based on the molecular and biological functions of the genes entailed the
deleted regions, which contain CTSK, ARNT, and ACTN4, we proposed that these two
candidate genomic deletions might be associated with preeclampsia. In a further attempt to
replicate our findings in an independent dataset that contains 1200 white European babies,
we did not find genes matched with our highest ranking candidates; however, one specific
gene RYR1 deletion was identified in both datasets, and it can also be found in an
established genetic database of preeclampsia genes. Our study was aimed to better
understand the etiology of preeclampsia and in hopes to develop better screening tools
based on genetic variants carried by the predisposed mother or fetus in the coming future.
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Introduction
Among pregnant women in the US, approximately 6-8% develop high blood pressure annually;
the underlying hypertensive disorders are the top cause of maternal death during pregnancy1.
Preeclampsia (PE) is one of the serious hypertensive disorders that are characterized by newly
onset hypertension and proteinuria, which usually starts after 20 weeks of gestation, and occurs
in about 5-8% of pregnancies worldwide2. When preeclampsia further progresses to eclampsia
(seizure), the condition is highly dangerous and can be fatal to both mother and the baby. There
is still no way to predict and prevent preeclampsia, and the only known cure so far is delivery of
the baby and complete removal of the conception products, which also turns out to be the leading
cause of preterm birth nowadays3.
Preeclampsia has been shown in several studies with familial heredity4-6. However, the
underlying genetic contributors remained elusive, and how these vary among racial groups is
poorly understood. A number of candidate genes that have been indicated in the pathogenesis
pathways involved in preeclampsia, including those related to immune dysfunction7, placenta
ischemia, hypoxia or oxidative stress8, 9. Even though many candidate gene approach studies
have been performed, the findings are inconclusive10, probably because of an still incomplete
understanding of the underlying biological mechanisms involved in preeclampsia pathogenesis
pathways to date11. Moreover, genome-wide association studies today mainly focus on single
nucleotide polymorphisms (SNPs), which are the most frequent point mutations but only
represented one part in the complicated genetic variations in associated with diverse diseases.
Considerations that are specifically in the maternal genetic contributions but limited studies from
the fetus side created barriers in understanding of preeclampsia heritability as well. There is now
accumulated evidence from both epidemiological and genetic studies suggest a fetal role in the
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etiology of preeclampsia5, 6; family study models also pointed out fetal determinants in
susceptibility to preeclampsia7, 12. A large epidemiological study from Sweden unraveled role of
genes expressed by the fetus in preeclampsia13. In the results they concluded that while 35% of
the genetic variability in preeclampsia was attributable to maternal genetics alone, 20% could be
attributed to fetal genetics alone, with the remainder unaccounted for. Nevertheless, we are still
lacking published candidate gene association studies that have examined the role of specific fetal
genetic variants on risk of preeclampsia.
DNA structural variation—the copy number variations (CNVs)— is responsible for human
evolution and is crucial for creating genetic diversity between individuals14. Although copy
number variations are less common than SNP point mutations, the structural variation can lead to
larger functional effects and make it susceptible to disease traits. Copy number variations
involved deletions or duplications at distinct regions on the genome. They can functionally alter
gene rearrangement by several mechanisms, including gene interruption, gene fusion, or
alteration at the regulatory regions, which may lead to dose-sensitive genomic disorders. Several
diseases have been found to be associated with copy number variations, such as sporadic
chromosomal microdeletion Prader-Willi and DiGeorge syndromes15, and therefore copy number
variations might be the missing puzzle that can help us dissecting the complex heritability of
preeclampsia.
Genome-wide association study (GWAS) is a hypothesis-free approach for uncovering the
genetics of preeclampsia. Built upon our preliminary genome-wide study of maternal copy
number variants in associated with preeclampsia16, our current study is conducted to identify
potential fetal SNPs and copy number variations that are associated with preeclampsia in the
mother using a case-control study design.
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Materials and Methods
Ethics statement
We received approval from the University of Iowa Institutional Review Board and the Yale
University Human Investigation Committee.
Study population
In order to maintain homogeneity in the preeclampsia phenotype, all of the children enrolled
in our study were delivered by white Caucasian mothers of primiparous, without history of
pre-existing hypertension, and delivered singleton live births. The mothers of the children were
originally recruited for the Study of Pregnancy Hypertension in Iowa (SOPHIA), which was a
case-control approach designed to examine the effects of maternal-fetal HLA sharing on risk of
preeclampsia. These mothers were initially identified for the SOPHIA study through birth
certificates provided by the Iowa Department of Public Health within 9 months of delivery, from
August 2002 to May 2005. All mothers who were recorded positive on the birth certificate for
pregnancy-induced hypertension or eclampsia were considered potential mothers of the cases,
and a random sample of the mothers who were recorded negative were considered as potential
mothers of the controls. Those who consented were further determined for initial eligibility. For
both cases and controls, exclusion criteria included mothers’ age less than 18 years at delivery;
non-English-speaking; history of an autoimmune disease (systemic lupus erythematosus, type 1
diabetes mellitus, rheumatoid arthritis, etc.); recurrent spontaneous abortion ( more than 3
sequential pregnancy losses); chronic hypertension; multiplegestation; major congenital
anomalies; and infant death. Mothers who met initial eligibility criteria were invited to
participate in the SOPHIA study and asked to complete an extensive telephone interview
collecting information on family history of cardiovascular and renal diseases and preeclampsia,
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and a detailed sexual history with the children’s father. A package containing buccal cell
collection kits for the mother and her child, the medical record release forms and consent forms
were mailed to the mothers, and they were asked to return the signed forms with buccal cell
samples as soon as possible in the pre-paid postage envelope. DNA was extracted from the
buccal samples and stored for analysis. Medical records were abstracted using a structured
abstraction form collecting detailed information on blood pressure and urinary protein values
during the prenatal, intrapartum, and immediate postpartum periods, along with information on
potential exclusion criteria (diabetes, SLE, preexisting hypertension, etc.) for both mothers of
cases and controls. To identify cases’ mothers, preeclampsia was defined according to the
National Heart, Lung and Blood Institute (NHLBI) guidelines. Based on chart review, 288 study
subjects, including 183 children of preeclamptic mothers and 105 children of non-preeclamptic
mothers met the strict case and control criteria (Figure 1). Regarding to replicating our findings
discovered in the SOPHIA study, we used white European subjects from the HAPO
(Hyperglycemia and Adverse Pregnancy Outcome) study as to confirm our results. Detailed PE
phenotypic definition and how we drawn our eligible study subjects (Figure 7) have been
described in our previous publication17.
Definition of preeclampsia
Criteria of preeclampsia were defined by the National Heart, Lung and Blood Institute
(NHLBI) guidelines. The criteria required: 1) newly onset hypertension (>140mmHg systolic or
>90mmHg diastolic on two or more occasions at least six hours apart beginning after the 20th
week of gestation; 2) accompanied with proteinuria, defined as urinary protein concentrations of
30mg/dL or greater (equivalent to dipstick value of 1+ from two or more specimens collected at
least four hours apart, or one or more urinary dipstick values of 2+ near the end or pregnancy, or
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one or more catheterized dipstick values of 1+ during delivery hospitalization, or 24-hour urine
collection with protein of ≧300mg. We excluded those children whose mothers for whom
pre-existing hypertension could not be ruled out (ie. no readings available prior to 20th weeks of
gestation; medical charts indicating chronic hypertension in the patient); or whom only met
partial criteria for preeclampsia (pregnancy-induced hypertension; proteinuria without
hypertension); or whom had incomplete information so a definitive diagnosis could not be made.
For those mothers of the control children, status was defined as a healthy, term delivery
without evidence of maternal high blood pressure in the prenatal, intrapartum, or postpartum
periods, no chronic hypertension, and no proteinuria (1+ on dipstick on two or more occasions).
GWAS genotyping
DNA samples, which previously isolated from buccal cells and stored at -20°C, were arrayed
on 96-well plates, 1µg of DNA at 50ng/µL, submitted to the Yale Center for Genome Analysis
for processing, using the Illumina Human OmniExpress microarray for a total genetic probes of
731,442 on each chip.
SNP analysis
PLINK18 analysis toolset was applied for genetic marker quality control. We first excluded
those individuals with genotyping call rate lower than 95% (n= 2 cases and 3 controls). SNPs
were next examined and removed if they met any of the following criteria: 1) not having a
genotyping call rate of 98% in either the cases or controls; 2) minor allele frequency (MAF) was
less than 2%; 3) violation of the Hardy Weinberg Equilibrium (HWE) as p-values less than 1 x
10-7. Q-Q plot showed no evidence of population stratification (no significant deviation, data not
shown). Finally we had 283 study subjects (181 cases and 102 controls) and 647,382 SNPs to
carry out the association analysis. Individual SNP was tested for both allelic and genotypic
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associations by calculating Fisher’s exact p-values and using a strict Bonferroni-corrected
genome-wide significant threshold at 7.72 × 10-8 (α = 0.05/647,382).
Detection of copy number variants
We applied three algorithms to insure higher quality of CNV calls (Figure 2). The
PennCNV19(June 16, 2011 version), QuantiSNP20(version 2.3 beta) and GNOSIS (bundled in
CNVision21 version 1.73) were used for CNV calls. Hidden Markov model based transitional
probabilities were behind PennCNV and QuantiSNP algorithms that integrated log R ratio (LRR:
a measure of total signal intensity of probes) and B allele frequency (BAF: a measure of relative
intensity ratio of allelic probes) to infer CNV calls for individual genotyping sample. GNOSIS
implements a continuous distribution function in sliding windows along the chromosomes to
detect CNVs by using log R ratio and B allele frequency as well. Detection algorithms’
command lines were run under default settings for Illumina HumanOmniExpress-12 v1.1 B
microarray; LRR and BAF raw fluorescent intensities were generated and exported from
Illumina GenomeStudio software.
The large number of CNV calls may reflect low DNA sample quality and false positive
discovery22, therefore stringent quality control criteria are essential to maintain valid CNV calls.
A single CNV might be detected multiple times due to fragmentation23, so we excluded those
CNVs called by less than ten consecutive SNP or CNV probes first, as PennCNV suggested
default CNV call QC criterion. We then log10-transformed the right-skewed distribution sample
calls for each algorithm to correct non-normality. A study subject was considered to have failed
CNV calls quality control and removed from further analysis (n = 7 cases and 5 controls) if
he/she had an extremely large number of CNV calls, defined as having CNV calls greater than
mean+3SD of the log10-transformed number of calls, presented in at least one of the three
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algorithms.
CNVision24 was used to analyze the merged CNV calls from PennCNV, QuantiSNP and
GNOSIS. The merge function of CNVision combined CNV calls made by all three algorithms
that had overlaps of ≥1 base pair and determined the percentage of call overlaps from specific
algorithms. Merged CNV calls were excluded (n = 43,172) if one of the following conditions
were met: 1) both deletion and amplification calls were made concurrently by different
algorithms at the same overlap region; 2) <50% overlap between two algorithms and <25%
overlap among three algorithms (Figure 3).
Prioritization of copy number variants
The recurrent function of CNVision screened copy number varied regions to extract those
overlaps across our study subjects that were presented more frequently in the cases, and those
overlapped regions containing less than five consecutive SNP or CNV probes were excluded
along the process (Figure 3). We used a subjective prioritization strategy to further generate
targeted CNV regions that were mostly enriched among cases: CNVs with odds ratios ≥ 2.25
comparing children of preeclamptic mothers to children of non-preeclamptic mothers, or CNVs
called in ≥3 cases but 0 in controls were then selected as candidates. Recurrent regions
overlapping centromeric (±100kb) and telomeric (±500kb within the start or end region of a
chromosome) regions were removed by using PennCNV bundled filtering script. We also
checked with public available online databases to exclude non-unique copy number
polymorphisms that are present in the general and healthy population. (Database of Genomic
Variants: http://dgv.tcag.ca/dgv/app/home; The Copy Number Variation Project:
http://cnv.chop.edu).

7

Results
SNP Association
A total of 283 genotyped study subjects (181 children of PE case mothers and 102 children of
control mothers) passed the default quality control call rate threshold (≧95%), with the overall
sample call rate reaching 99.94%. No SNPs surpassed the Bonferroni-corrected genome-wide
significant threshold of 7.72x10-8 for the Fisher’s exact genotypic or allelic tests. The top 2 SNP
candidates had a genotypic p-value less than 10-5 (Table 1).
CNV Detection
After merging CNV calls from all three CNV calling algorithms by using CNVision, a total of
4,388 overlapped CNVs across genome among 174 children of PE case mothers and 97 children
of control mothers met initial inclusion criteria. The length of these CNVs ranged from 24 bp to
24 Mb with an average of 65 kb. Of these CNVs, 3,334 showed deletions (including
homozygous and heterozygous deletions), and 1,054 were duplications. The CNVs were further
screened to extract those overlaps across our study subjects that were mostly enriched among the
cases, and those overlapped regions containing less than five consecutive SNP or CNV probes
were excluded along the process; 608 deleted regions and 279 duplicated regions were then
identified.
Among the 608 deleted regions, 25 candidates surpassed odds ratio ≥ 2.25 comparing children
of preeclamptic mothers to children of non-preeclamptic mothers, or CNVs called in ≥3 cases
but 0 in controls, as described in the method section; correspondingly, 10 copy-number
duplicated regions stood out to be candidates. We confirmed these candidate regions with the
public available copy number variation databases online (http://cnv.chop.edu;
http://dgv.tcag.ca/dgv/app/home) to exclude non-unique copy number polymorphisms that were
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present in the general and healthy population25. Of the 25 deleted regions, 20 were left to be
unique or not yet identified rare or low frequency CNVs; of the 10 duplicated regions, only 4
were left to be unique CNVs (Table 2).
Since loss of function of the protein products by homozygous or heterozygous deletions of
certain genes are more frequent and severe than gains of function by slightly duplicated copies of
the genes26, 27, we thus made deletions as a prioritized resource for exploring the genetic and
biological basis of PE phenotypic variation. Of the 20 deleted regions, we discovered two
interesting regions on chromosome 1q21.2 and 19q13.2 with the highest odds ratio rankings,
containing ARNT, CTSK and ACTN4 annotated genes. Based on the molecular and biological
regulatory functions of these genes, we proposed their associations with preeclampsia
pathogenesis (Table 3).
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Table 1 Association (p-value) of the top 2 SNP candidates with children of preeclampic
mothersa
SNPb

Minor allele
frequency (%)
Cases Controls
(n=181) (n=102)
rs359937
24.6
20.1
rs11627903
34.8
48.0
a

Fisher’s exact p-value
Genotypic

Allelic

4.62x10-6
5.04x10-6

2.53x10-1
2.33x10-3

Chr.

Position

SNP type

Closest
gene

Distance
to gene
(kb)

1
14

89982719
89484667

intergenic
intergenic

LRRC8B
TRNAA17

7.2
39

SNPs with genotypic p-values less than 10-5.
Ordered according to smallest to largest genotypic Fisher’s exact p-values.

b

11

12

13

14

15

16

17

18

19

20

Discussion
In our result, we initially identified 25 candidate copy-number deleted regions and 10
duplicated regions that mostly enriched in the children of the preeclamptic mothers. Since the
more common of the CNVs, the less possible they are associated with disease traits28, we
confirmed the none uniqueness of the CNVs we detected through The Copy Number Variation
Project (http://cnv.chop.edu) across healthy individuals, and the low to rare CNV frequencies in
the general population through the Database of Genomic Variants
(http://dgv.tcag.ca/dgv/app/home). Along the process of finding non-unique copy number
variable regions, we found that most fetal CNVs were “copy number polymorphisms29” that
might or might not have significant contributions to the preeclamptic mothers, and we ended up
with 20 novel deletion candidates and 4 duplicated candidates. We decided to focus on deletions
because loss of function of the protein products by homozygous or heterozygous deletions of
certain genes are more frequent and severe than gains of function by slightly duplicated copies of
the genes26, 27. The two fetal deleted regions we found most interesting on chromosome 1q21.2
and 19q13.2 respectively contain annotated genes of ARNT (aryl hydrocarbon receptor nuclear
translocator), CTSK (cathepsin K) and ACTN4 (alpha-actinin-4), that might have molecular and
biological effects in developing preeclampsia in the mothers. We postulated the post-translational
impairment of these protein functions due to copy number deletion.
The functional transcription factor exists as a heterodimeric complex consisting of the aryl
hydrocarbon receptor nuclear translocator (ARNT) and Hypoxia-inducible factor 1-alpha
(HIF-1α)30. HIF-1α is a principal mediator of hypoxic adaptations, modulates through
Wnt/β-catenin signaling in hypoxic status cells31. HIF-1α deletion has shown to impair
hippocampal Wnt-dependent processes, including cell proliferation, differentiation and

21

functional maturation. A recent integrative transcriptome meta-analysis using fetal-derived
histological subsections of placenta from multiple case-control preeclampsia studies pointed out
that the genes clustered in the HIF-1α signaling pathway are dysregulated in the fetus of
preeclamptic mothers9. This study also showed that the dominant genes involved in regulation of
hopoxic trophoblast are HIF-1α, HIF-2α and ARNT. Another study also pointed out that hypoxia
interferes with the differentiation of in vitro cultured cytotrophoblast into terminally
differentiated syncytiotrophoblast, through DNA hypermythylation and suppression of associated
genes32. The villi surfaced on syncytiotrophoblasts constitute the intervillous space which is
resposible for maternal blood inflow and maternal-fetal exchange during pregnancy. Therefore,
downregulated ARNT due to copy-number deletion might lead to unstable heterodimeric
complex with HIF-1α, cuasing abnormal HIF-1α function in the fetus, thereby increase oxidative
stress and provoke the risk of preeclampsia in the mother. CTSK mutation has been linked to a
rare autosomal recessive disease pychodysotosis, which is characterized by osteosclerosis and
short stature33. Moreover, co-culture of CTSK+ fibroblast with CTSK- breast cancer cells has
been found to enhance cancer cells invasion, and this enhanced invasive ability is blocked by
CTSK inhibitors34. CTSK might thus have a putative role in regulating trophoblast invasion into
maternal decidua, which is important in normal embryo implantation and the following process
of vascular remodeling, maintaining stable plancetal blood inflows to the survival and growth of
the fetus. CTSK downregulation might lead to defective trophoblast invasion and plancenta
maldevelopment, whereas increase the possibility of ischemia in the fetus and preeclampsia in
the mother. Mutation of ACTN4 has been linked to familial focal segmental glomerulosclerosis,
which is a rare autosomal dominant disease characterized by increased urinary protein excretion
and decreasing kidney function35. Reduced ACTN4 mRNA expression might dysregulate the
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actin cytoskeleton of glomerular podocytes and increase protein filtration into urine. There are
gradually growing statistical findings from large datasets or cohort studies pointing out the
gene-environment interactions in the uterus between the fetus and the preeclamptic mother6, 9, 13,
36

, but there is still lack of direct biological and mechanistic evidence showing how the abnormal

infant genes influence maternal health during pregnancy. Though nutrients and wastes exchange
between the fetus and the mother, it is still unknown how extra protein excreted by the fetus into
amniotic fluid would end up elevates proteinuria in the mother. We thus speculated about the
possibility that the deleted fashion of ACTN4 in the infants might be passed down from the
abnormality in the mothers, however, we didn’t find direct evidence in reviewing the data from
our previous study16.
In a further attempt to replicate our findings in the HAPO study (Figure 8), we didn’t discover
matched deleted regions with those we found the most interesting regions containing ARNT,
CTSK, and ACTN4 genes in the SOPHIA study. However, in the SOPHIA study, the deleted
region upstream of ACTN4 gene that also resides in chromosome 19q13.2 contains a large part
of RYR1 gene deletion (Figure 6). We not only found a match for it in the HAPO study, but also
found a documented match that already linked fetal deletion to an association with preeclamptic
mothers from an established preeclampsia gene database37. RYR1 is known as ryanodine
receptor 1, which is part of the family of ryanodine receptors that form channels to transport
positively charged calcium ions within cells38. One study compared mRNA and protein levels
expressed by cultured primary syncytiotrophoblasts (the outer syncytial layer of the trophoblast
that actively invades the uterine wall forming the outermost fetal component of the placenta)
obtained from normal and preeclamptic mothers, and they found a significant decrease in
calcium transport by the syncytiotrophoblast cultured from preeclamptic placentas and a
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downregulation of RYR1 mRNA expression39. Based on systematic reviews of accumulated
observational studies that found calcium supplementation may reduce the risk of preeclampsia
and may help to prevent preterm birth40, 41, WHO also recommend on populations where calcium
intake is low to take calcium supplementation as part of the antenatal care for the prevention of
preeclampsia in pregnant women, particularly among those at higher risk of developing
hypertension (http://www.who.int/elena/titles/calcium_pregnancy/en/). Fetal RYR1 gene deletion
clearly plays a role in the development of preeclampsia in the mothers, which interferes with
calcium transportation during trophoblast invasion that determines a successful pregnancy.
Identification of this known preeclampsia associated RYR1 gene deletion in both SOPHIA and
HAPO studies further attests the appropriateness of the procedure we preformed to generate
prioritized candidate regions of CNVs in our study.
Note that the strategy we implemented to determine targeted CNVs by odds ratio in the cases
versus controls was completely subjective in our study; moreover, due to limited number of the
study subjects, the CNV frequencies comparing cases to controls were usually low, which limited
the power of our analyses, resulted in wide 95% confidence intervals (data not shown).
Genome-wide association study is a hypothesis-free approach that screens the entire genome
for associations between genetic polymorphisms and a certain disease. The most important
methodological issue with GWAS studies is multiple comparisons, which needs to be addressed
by strictly statistical significance level correction and further replicative studies, and yet this
corrected genome-wide significant level usually makes it difficult to find stringent result as can
been seen in our study. The limitations of GWAS studies also includes the inability to detect
associations between rare variants (prevalence < 2%) and the disease, where we assumed to be
genotyping error and eliminated at the quality control step. We also excluded those SNPs at the
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quality control step which violated of the Mendelian inheritance or Hardy-Weinberg equilibrium,
where none in fact really existed42, 43 due to the intrinsic that allelic or genotypic frequencies in a
population will remain constant from generation to generation in the absence of other sporadic
evolutionary influences. In addition, GWAS only identifies a genomic location associated with
the disease, but not proving a causal polymorphism, because GWA studies are unable to provide
information on biological mechanisms underlying the association, which requires further
molecular biology studies to fortify our understanding.
Although our genome is born to be what it is, the difference between incidence case and
prevalence case determined the genetic variations for incidences and survivors, which reflects
divergent indications of the disease statuses. Recently the concept of endophenotypes, which
involve multiple biological, behavioral or cognitive features to the vulnerability of a certain
disorder44, might help explain the complex mechanisms contribute to preeclampsia. Since
preeclampsia is defined by both gestational hypertension and proteinuria, these two traits might
be determined by different genetic variations that are closely related to each other. For example,
abnormality in the vasopressin gene might affect electrolytes metabolism, cause retention of
sodium in the blood and elevation of blood volume and pressure45; insulin resistant
predisposition might be related to diabetic and hypertensive traits; long-term stimulation of
sympathetic nervous system by stress might contribute to hypertension as well; hypoxia and
oxidative stress has been shown to interfere with placenta development by dysregulation of the
EGFR growth factor signaling pathway to blood vessel defects in placenta9; although rare,
genotype-phenotype defects in any of the components involved in glomerular filtration system
can result in proteinuria46, etc. Although not every individual carrying certain genes will result in
phenotypic expression, these people might still possess higher risk of preeclampsia during
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pregnancy. Moreover, in order to prevent population stratification, we only enrolled children
from white mothers in our study, therefore the preeclamptic genetic variants across
multi-ethnicity are left for further investigation.
In conclusion, dysfunctional protein regulation in the fetus due to copy number deletion might
or might not directly influence the mother. However, our study pointed out possible roles of
ARNT, CTSK and ACTN4 gene deletions in the fetus that are associated with hypoxia
modulation, postulated regulation of trophoblast invasion, and abnormal proteinuria in the fetus
respectively, which need further biological experiments to substantiate the functional protein
expression in associated with increased risk of preeclampsia in the mother. The long term goal of
our study is to better understand the etiology of preeclampsia and in hopes to develop better
screening tools based on genetic variants carried by the predisposed mother or fetus. With more
thorough considerations of various genetic variations, including rare or common SNPs and
CNVs, applying the concept of endophenotypes, and using integrative omics approaches, might
one day help us decipher causal or etiological determinants among existing association studies,
to more effectively intervene and prevent preeclampsia in susceptible individuals in a timely
manner.
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